M
Monica Lambley
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
Jul 30, 2026
Be Risk Ready – a PDL Podcast: You’ve received an Ahpra notification, now what?
7:27
7:37
7:50
7:58
8:05
A
7:17Aimee MinionHOST
So Monica, what sorts of things would a regulator be looking for in their assessment of a notification and how an outcome might be reached?

Monica LambleyGUEST
And I think the first thing I want to talk about is that almost all of our pharmacy notifications are reviewed by a pharmacist employed at AHPRA as a clinical advisor.

Monica LambleyGUEST
So the clinical advisors will, when the notification first comes in or the information is first received, they'll look at that information and determine if we do need further information either from a practitioner or from another source.

Monica LambleyGUEST
They'll also work alongside the case manager throughout the notifications process to assess any information we receive and if we need to get further information.

Monica LambleyGUEST
So we have a really strong clinical input across the notifications and compliance processes at AHPRA.

Monica LambleyGUEST
The information that we are seeking is often quite a small amount of information, and it usually just needs to be about confirming the information that we have or responding to a question that we might have.
A
12:26Aimee MinionHOST
So Monica, how can practitioners show accountability and insight to support remediation and reduce the risk of further regulatory action?